【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 27
2.1 Related Reports 28
3 Disease Overview 29
3.1 Macular Degeneration Overview 29
3.1.1 Etiology and Pathophysiology 31
3.1.2 Classification 35
3.1.3 Symptoms and Diagnosis 37
3.2 Macular Edema Overview 40
3.2.1 Etiology and Pathophysiology 41
3.2.2 Classification 44
3.2.3 Symptoms and Diagnosis 45
4 Epidemiology – Macular Edema 48
4.1 Disease Background 48
4.2 Risk Factors and Comorbidities 48
4.3 Global Trends 49
4.3.1 US 50
4.3.2 5EU 50
4.3.3 Japan 51
4.4 Forecast Methodology 51
4.4.1 Sources Used 52
4.4.2 Sources Not Used 54
4.4.3 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes 55
4.4.4 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetic Retinopathy 59
4.4.5 Forecast Assumptions and Methods – Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 60
4.4.6 Forecast Assumptions and Methods – Total Prevalent Cases of ME following BRVO and CRVO 61
4.5 Epidemiological Forecast for Macular Edema (2013-2023) 62
4.5.1 Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 62
4.5.2 Age-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 64
4.5.3 Sex-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 66
4.5.4 Total Prevalent Cases of ME Following BRVO 68
4.5.5 Age-Specific Total Prevalent Cases of ME Following BRVO 70
4.5.6 Sex-Specific Total Prevalent Cases of ME following BRVO 72
4.5.7 Total Prevalent Cases of ME Following CRVO 74
4.5.8 Age-Specific Total Prevalent Cases of ME Following CRVO 76
4.5.9 Sex-Specific Total Prevalent Cases of ME Following CRVO 78
4.6 Discussion 80
4.6.1 Epidemiological Forecast Insight 80
4.6.2 Limitations of the Analysis 81
4.6.3 Strengths of the Analysis 82
5 Epidemiology – Age-Related Macular Degeneration 83
5.1 Disease Background 83
5.2 Risk Factors and Comorbidities 84
5.3 Global Trends 85
5.3.1 US 85
5.3.2 5EU 86
5.3.3 Japan 86
5.4 Forecast Methodology 87
5.4.1 Sources Used 88
5.4.2 Forecast Assumptions and Methods 90
5.5 Epidemiological Forecast for AMD (2013-2023) 94
5.5.1 Total Prevalent Cases of AMD 94
5.5.2 Age-Specific Total Prevalent Cases of AMD 95
5.5.3 Sex-Specific Total Prevalent Cases of AMD 97
5.5.4 Age-Standardized Total Prevalence of AMD 99
5.5.5 Total Prevalent Cases of AMD by Stage 101
5.5.6 Total Prevalent Cases of Late AMD by Subtype 102
5.6 Discussion 104
5.6.1 Epidemiological Forecast Insight 104
5.6.2 Limitations of the Analysis 105
5.6.3 Strengths of the Analysis 106
6 Disease Management 107
6.1 Diagnosis and Treatment Overview 107
6.1.1 Macular Edema Diagnosis 107
6.1.2 Macular Degeneration Diagnosis 107
6.1.3 Treatment Guidelines and Leading Prescribed Drugs 108
6.1.4 Clinical Practice 110
6.2 US 123
6.3 France 127
6.4 Germany 130
6.5 Italy 133
6.6 Spain 136
6.7 UK 139
6.8 Japan 142
7 Competitive Assessment 145
7.1 Overview 145
7.2 Product Profiles – Major Brands 146
7.2.1 Lucentis (ranibizumab) 146
7.2.2 Eylea (aflibercept) 157
7.2.3 Avastin (bevacizumab) 168
7.2.4 Macugen (pegaptanib sodium) 175
7.2.5 Visudyne (verteporfin) 178
7.2.6 Corticosteroid Implants 183
8 Unmet Need and Opportunity 195
8.1 Overview 195
8.2 Treatment for Dry AMD 196
8.2.1 Unmet Need 196
8.2.2 Gap Analysis 198
8.2.3 Opportunity 200
8.3 Longer-Acting Anti-VEGF Drug Therapy 202
8.3.1 Unmet Need 202
8.3.2 Gap Analysis 204
8.3.3 Opportunity 204
8.4 Increased Efficacy of Anti-VEGF Therapy for wAMD 205
8.4.1 Unmet Need 205
8.4.2 Gap Analysis 206
8.4.3 Opportunity 207
8.5 Less Invasive Drug Formulations 207
8.5.1 Unmet Need 207
8.5.2 Gap Analysis 208
8.5.3 Opportunity 209
8.6 Awareness and Earlier Patient Diagnosis 210
8.6.1 Unmet Need 210
8.6.2 Gap Analysis 211
8.6.3 Opportunity 211
8.7 Home Monitoring of AMD Progression 212
8.7.1 Unmet Need 212
8.7.2 Gap Analysis 213
8.7.3 Opportunity 214
9 Pipeline Assessment 216
9.1 Overview 216
9.2 Clinical Trial Mapping 217
9.3 Promising Drugs in Clinical Development 218
9.3.1 Abicipar pegol 220
9.3.2 Fovista 227
9.3.3 Squalamine 235
9.3.4 Lampalizumab 243
9.3.5 Emixustat 250
9.3.6 Optina 257
9.3.7 DE-102 265
9.4 Promising Drugs in Early-Stage Development 269
9.4.1 Complement Inhibitors 269
9.5 Other Drugs in Development 271
9.6 Biosimilars 273
10 Current and Future Players 275
10.1 Overview 275
10.2 Trends in Corporate Strategy 277
10.3 Company Profiles 278
10.3.1 Roche/Genentech 278
10.3.2 Novartis 282
10.3.3 Regeneron 285
10.3.4 Bayer 289
10.3.5 Valeant 293
10.3.6 Allergan 296
10.3.7 Alimera Sciences 299
10.3.8 Ampio Pharmaceuticals 303
10.3.9 Ophthotech 305
10.3.10 Acucela 309
10.3.11 Ohr Pharmaceuticals 313
11 Market Outlook 316
11.1 Global Markets 316
11.1.1 Forecast 316
11.1.2 Drivers and Barriers – Global Issues 324
11.2 US 327
11.2.1 Forecast 327
11.2.2 Key Events 333
11.2.3 Drivers and Barriers 333
11.3 France 335
11.3.1 Forecast 335
11.3.2 Key Events 341
11.3.3 Drivers and Barriers 341
11.4 Germany 345
11.4.1 Forecast 345
11.4.2 Key Events 350
11.4.3 Drivers and Barriers 350
11.5 Italy 353
11.5.1 Forecast 353
11.5.2 Key Events 360
11.5.3 Drivers and Barriers 360
11.6 Spain 364
11.6.1 Forecast 364
11.6.2 Key Events 369
11.6.3 Drivers and Barriers 369
11.7 UK 372
11.7.1 Forecast 372
11.7.2 Key Events 378
11.7.3 Drivers and Barriers 378
11.8 Japan 382
11.8.1 Forecast 382
11.8.2 Key Events 388
11.8.3 Drivers and Barriers 388
12 Appendix 392
12.1 Bibliography 392
12.2 Abbreviations 427
12.3 Methodology 434
12.4 Forecasting Methodology 434
12.4.1 Diagnosed ME and AMD Patients 434
12.4.2 Percentage of Drug-Treated Patients 435
12.4.3 Drugs Included in Each Therapeutic Class 435
12.4.4 Launch and Patent Expiry Dates 435
12.4.5 General Pricing Assumptions 436
12.4.6 Individual Drug Assumptions 437
12.4.7 Pricing of Pipeline Agents 442
12.5 Primary Research – KOLs Interviewed for this Report 443
12.6 Primary Research – High-Prescribers Survey 444
12.7 About the Authors 445
12.7.1 Analyst 445
12.7.2 Therapy Area Director 445
12.7.3 Epidemiologist 446
12.7.4 Global Head of Healthcare 446
12.8 About GlobalData 447
12.9 Disclaimer 447
【レポート販売概要】
■ タイトル：黄斑浮腫・黄斑変性治療薬の世界市場予測および分析■ 英文：PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
■ 発行日：2014年10月31日
■ 調査会社：GlobalData
■ 商品コード：GDHC111PIDR
■ 調査対象地域：グローバル
- 指圧痕用独立型スキャナの世界市場2016-2020About Digital Impression Standalone Scanners Digital impression standalone scanners are used to capture accurate digital impressions of the components of visible hard and soft tissues. They are used as a substitute for conventional elastomeric material (a polymer with viscoelasticity). These scanners use LEDs, lasers, or other optical sources to scan intraoral images to make 3D images of intraoral …
- Wi-Fiダイレクトソリューション及びアプリケーション（Wi-Fi Direct Solutions and Applications）WiFi Direct allows devices to communicate directly with each other using methods similar to traditional WiFi without the reliance upon a central access point. Instead, the devices use a “Software Access Point” (Soft AP). When two devices get within close range of each other the users can merely push a button which will allow the devices to communicate directly with one another and negotiate which …
- 医療コーティングの世界市場予測：親水性塗料、疎水性塗料The global medical coatings market is projected to grow at a CAGR of 7.04% from 2016 to reach USD 15.15 Billion by 2021. The market is highly driven by the awareness about healthcare acquired infections and minimally invasive surgery. Another prime factor that is expected to bring momentum to this market is the increasing ageing population globally and rising awareness about health-care and govern …
- デジタルサイネージ及び業務用ディスプレイ用LEDの世界市場The worldwide consumption of packaged light emitting diodes in signage and professional displays reached $2.011 billion in 2014. In the year 2019, consumption is forecast to reach $3.56 billion. The consumption value in Dual In-line Package (DIP) LEDs is forecast to increase in value at over 20 percent per year; however, Surface Mount Diode (SMD) LEDs are forecast with negative growth as Chip-On-B …
- 創薬アウトソーシングの世界市場予測2016-2026Where is the drug discovery outsourcing market heading? Visiongain’s new report gives you revenue predictions for the drug discovery outsourcing market and its submarkets from 2016 to 2026, helping you stay ahead. Visiongain’s new 232-page report provides revenue forecasts to 2026 for the global drug discovery outsourcing market, four leading submarkets and 13 leading national markets. The report …
- Strong Nuclear Power Demand to Drive the Uranium MarketStrong Nuclear Power Demand to Drive the Uranium Market Summary The growing number of nuclear installations is generating huge demand for uranium. Despite anti nuclear concerns, many countries are focusing on increasing the nuclear share in their energy mix due to increasing greenhouse gas emissions, growing power demand, and the volatility of fossil fuel prices. This growth will generate huge dem …
- 世界における麻酔器の製品パイプライン動向2015Anesthesia Machines - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Anesthesia Machines - Pipeline Review, 2015" provides an overview of Anesthesia Machines currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players invol …
- 子宮頸がん診断検査の世界市場2016-2020About Cervical Cancer Diagnostic Testing The global cervical cancer diagnostic testing market is growing steadily, primarily due to the availability and awareness of the programs in the developed countries. This test enables women aged 21 years and above to get screened, making most of the pre-cancerous lesions identifiable at stages when they can be treated easily. In the US, National Breast and …
- Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis)：市場予測と分析（～2022）Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvemen …
- 自動車用ゴムホースの世界市場2016-2020Automotive rubber hoses are widely used in radiators, heaters, automatic transmission systems, brake systems, fuel and emission systems, lubrication systems, and AC systems in automobiles. Molded and extruded hoses are the two main types of rubber hoses used in the automotive industry. Typically, a hose consists of an inner tube reinforced with an outer tube to enhance the ability to withstand dif …
- 電気フライヤーの世界市場：ディープファットフライヤー、エアフライヤーAbout electric fryers An electric fryer is used for making the process of frying food less cumbersome. It is used in residential as well as commercial segments. This report focusses on the electric fryers for the residential segment. The presence of deep fat fryers and air fryers in the market meets the need of health conscious consumers. The increased health consciousness and rising incidence of …
- グローバル菓子類市場2014：ブリーフィング資料This latest briefing from just-food on global confectionery analyses some of the key issues facing the sector - and interviews some of the leading players in the sector. From the recent heightened scrutiny on sugar and confectionery's alleged role in obesity to dealing with the intractable issue of child labour and from the two-speed market for chewing gum and the potential of developing economies …
- 結腸ステントのアメリカ市場：ニチノール自己拡張型金属ステント（SEMS）、エルジロイ（自己拡張型金属ステント（SEMS））The U.S. colonic stents market was valued at $6.44 million in 2018 and is projected to reach $9.41 million by 2026, registering a CAGR of 4.8% from 2019 to 2026. A colonic stent is used to relieve acute colonic obstruction in colorectal cancer patients. The stent is compressed tightly onto a small delivery wire that allows the stent to be positioned across the tight narrowing to relieve blockage i …
- 胃損傷(Gastric Injury)：世界の治験レビュー（2015年上半期版）Gastric Injury Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Gastric Injury Global Clinical Trials Review, H1, 2015" provides data on the Gastric Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastric Injury. It includes an overview of the trial numbers and their recruitment status as per …
- Marquee Energy Ltd.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Marquee Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Marquee Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
